PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Avenue Therapeutics, Inc. (ATXI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS05360L2051
CUSIP05360L205
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$5.75M
EPS-$0.98
Year Range$0.11 - $1.25
Target Price$0.75
Short %0.65%
Short Ratio0.15

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Avenue Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Avenue Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2024FebruaryMarchApril
-79.10%
18.81%
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Avenue Therapeutics, Inc. had a return of -19.19% year-to-date (YTD) and -87.37% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-19.19%5.05%
1 month-13.96%-4.27%
6 months-78.31%18.82%
1 year-87.37%21.22%
5 years (annualized)-71.80%11.38%
10 years (annualized)N/A10.42%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-8.07%2.50%-2.77%
2023-8.89%-66.76%-9.79%-24.06%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ATXI is 10, indicating that it is in the bottom 10% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ATXI is 1010
Avenue Therapeutics, Inc.(ATXI)
The Sharpe Ratio Rank of ATXI is 1919Sharpe Ratio Rank
The Sortino Ratio Rank of ATXI is 88Sortino Ratio Rank
The Omega Ratio Rank of ATXI is 77Omega Ratio Rank
The Calmar Ratio Rank of ATXI is 44Calmar Ratio Rank
The Martin Ratio Rank of ATXI is 1111Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Avenue Therapeutics, Inc. (ATXI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ATXI
Sharpe ratio
The chart of Sharpe ratio for ATXI, currently valued at -0.64, compared to the broader market-2.00-1.000.001.002.003.00-0.64
Sortino ratio
The chart of Sortino ratio for ATXI, currently valued at -1.52, compared to the broader market-4.00-2.000.002.004.00-1.52
Omega ratio
The chart of Omega ratio for ATXI, currently valued at 0.78, compared to the broader market0.501.001.500.78
Calmar ratio
The chart of Calmar ratio for ATXI, currently valued at -0.88, compared to the broader market0.001.002.003.004.005.00-0.88
Martin ratio
The chart of Martin ratio for ATXI, currently valued at -1.39, compared to the broader market0.0010.0020.0030.00-1.39
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.81, compared to the broader market-2.00-1.000.001.002.003.001.81
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.64, compared to the broader market-4.00-2.000.002.004.002.64
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.001.002.003.004.005.001.38
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Avenue Therapeutics, Inc. Sharpe ratio is -0.64. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.64
1.81
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Avenue Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.93%
-4.64%
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Avenue Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Avenue Therapeutics, Inc. was 99.93%, occurring on Feb 6, 2024. The portfolio has not yet recovered.

The current Avenue Therapeutics, Inc. drawdown is 99.93%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.93%Sep 15, 2020851Feb 6, 2024
-74.55%Jun 28, 2017325Oct 10, 2018304Dec 26, 2019629
-43.11%Feb 11, 202026Mar 18, 202050May 29, 202076
-18.31%Jun 1, 202030Jul 13, 202026Aug 18, 202056
-11.46%Jan 2, 202010Jan 15, 20208Jan 28, 202018

Volatility

Volatility Chart

The current Avenue Therapeutics, Inc. volatility is 15.48%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%NovemberDecember2024FebruaryMarchApril
15.48%
3.30%
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Avenue Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items